Shikonin inhibits the migration and invasion of human glioblastoma cells by targeting phosphorylated β-catenin and phosphorylated PI3K/Akt: A potential mechanism for the anti-glioma efficacy of a traditional Chinese herbal medicine

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 23823-23848

  Zhang, Feng Ying ^a   Hu, Yi ^a   Que, Zhong You ^a   Wang, Ping ^a   Liu, Yun Hui ^a   Wang, Zhen Hua ^a   Xue, Yi Xue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Invasion; Migration; Phosphorylated PI3K Akt; Shikonin; catenin

Indexed keywords

BETA CATENIN; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHIKONIN; HERBACEOUS AGENT; IGF1 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NAPHTHOQUINONE; SMALL INTERFERING RNA; SOMATOMEDIN C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CHINESE MEDICINE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEOPLASM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLIOBLASTOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUGS, CHINESE HERBAL; GLIOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEDICINE, CHINESE TRADITIONAL; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84944097676     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161023823     Document Type: Article

References (60)

1. Yin, C.L.; Lv, S.Q.; Chen, X.Y.; Guo, H. The role of glioma stem cells in glioma tumorigenesis. Front. Biosci. 2014, 19, 818–823.
2. Stupp, R.; Tonn, J.C.; Brada, M.; Pentheroudakis, G.; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21, v190–v193.
3. Lehrer, S.; Green, S.; Ramanathan, L.; Rosenzweig, K.; Labombardi, V. No consistent relationship of glioblastoma incidence and cytomegalovirus seropositivity in whites, blacks, and hispanics. Anticancer Res. 2012, 32, 1113–1115.
4. Crocetti, E.; Trama, A.; Stiller, C.; Caldarella, A.; Soffietti, R.; Jaal, J.; Weber, D.C.; Ricardi, U.; Slowinski, J.; Brandes, A. et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur. J. Cancer 2012, 48, 1532–1542.
5. Schwartzbaum, J.A.; Fisher, J.L.; Aldape, K.D.; Wrensch, M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2006, 2, 494–503.
6. Siebzehnrubl, F.A.; Reynolds, B.A.; Vescovi, A.; Steindler, D.A.; Deleyrolle, L.P. The origins of glioma: E Pluribus Unum? Glia 2011, 59, 1135–1147.
7. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459–466.
8. Wang, Y.B.; Hu, Y.; Li, Z.; Wang, P.; Xue, Y.X.; Yao, Y.L.; Yu, B.; Liu, Y.H. Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells. PLoS ONE 2013, 8, e60834.
9. Lima, F.R.S.; Kahn, S.A.; Soletti, R.C.; Biasoli, D.; Alves, T.; da Fonseca, A.C.C.; Garcia, C.; Romão, L.; Brito, J.; Holanda-Afonso, R. et al. Glioblastoma: Therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 2012, 1826, 338–349.
10. Sanai, N.; Berger, M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62, 753–764.
11. Motsch, S.; Koschmann, C.; Calinescu, A.A.; Mineharu, Y.; Camelo-Piragua, S.I.; Orringer, D.; Bannykh, S.; Nichols, W.S.; deCarvalho, A.C.; Mikkelsen, T. Mechanisms of glioma formation: Iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 2014, 16, 543–561.
12. Skalli, O.; Wilhelmsson, U.; Orndahl, C.; Fekete, B.; Malmgren, K.; Rydenhag, B.; Pekny, M. Astrocytoma grade IV (glioblastoma multiforme) displays 3 subtypes with unique expression profiles of intermediate filament proteins. Hum. Pathol. 2013, 44, 2081–2088.
13. Hai, J.; Lin, Q.; Lu, Y.; Yi, J.; Zhang, H. Growth inhibition and induction of differentiation by panaxydol in rat C6 glioma cells. Neurol. Res. 2008, 30, 99–105.
14. Shao, J.; Zheng, D.; Jiang, Z.; Xu, H.; Hu, Y.; Li, X.; Lu, X. Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim. Biophys. Sin. 2011, 43, 267–274.
15. Andújar, I.; Ríos, J.L.; Giner, R.M.; Recio, M.C. Pharmacological properties of shikonin—A review of literature since 2002. Planta Med. 2013, 79, 1685–1697.
16. Lan, W.; Wan, S.; Gu, W.; Wang, H.; Zhou, S. Mechanisms behind the inhibition of lung adenocarcinoma cell by shikonin. Cell Biochem. Biophys. 2014, 70, 1459–1467.
17. Jang, S.Y.; Lee, J.K.; Jang, E.H.; Jeong, S.Y.; Kim, J.H. Shikonin blocks migration and invasion of human breast cancer cells through inhibition of matrix metalloproteinase-9 activation. Oncol. Rep. 2014, 31, 2827–2833.
18. Chen, Y.; Zheng, L.; Liu, J.; Zhou, Z.; Cao, X.; Lv, X.; Chen, F. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int. Immunopharmacol. 2014, 21, 447–455.
19. Gong, K.; Zhang, Z.; Chen, Y.; Shu, H.B.; Li, W. Extracellular signal-regulated kinase, receptor interacting protein, and reactive oxygen species regulate shikonin-induced autophagy in human hepatocellular carcinoma. Eur. J. Pharmacol. 2014, 738, 142–152.
20. Shi, S.; Cao, H. Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway. Oncol. Lett. 2014, 8, 1087–1089.
21. Zhang, F.L.; Liu, Y.H.; Liu, L.B.; Liu, X.B.; Xue, Y.X. Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS ONE 2013, 8, e81815.
22. Yang, J.T.; Li, Z.L.; Wu, J.Y.; Lu, F.J.; Chen, C.H. An oxidative stress mechanism of shikonin in human glioma cells. PLoS ONE 2014, 9, e94180.
23. Huang, C.; Luo, Y.; Zhao, J.; Yang, F.; Zhao, H.; Ge, P. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS ONE 2013, 8, e66326.
24. Pu, P.; Zhang, Z.; Kang, C.; Jiang, R.; Jia, Z.; Wang, G.; Jiang, H. Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009, 16, 351–361.
25. Paul, I.; Bhattacharya, S.; Chatterjee, A.; Ghosh, M.K. Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013, 4, 427–446.
26. Giles, R.H.; van Es, J.H.; Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 2003, 1653, 1–24.
27. Yano, H.; Hara, A.; Shinoda, J.; Takenaka, K.; Yoshimi, N.; Mori, H.; Sakai, N. Immunohistochemical analysis of β-catenin in N-ethyl-N-nitrosourea-induced rat gliomas: Implications in regulation of angiogenesis. Neurol. Res. 2000, 22, 527–532.
28. Forsyth, P.A.; Wong, H.; Laing, T.D.; Rewcastle, N.B.; Morris, D.G.; Muzik, H.; Leco, K.J.; Johnston, R.N.; Brasher, P.M.A.; Sutherland, G. et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 1999, 79, 1828–1835.
29. Hu, Y.; Lin, X.; Wang, P.; Xue, Y.X.; Li, Z.; Liu, L.B.; Yu, B.; Feng, T.D.; Liu, Y.H. CRM197 in combination with shRNA interference of VCAM-1 displays enhanced inhibitory effects on human glioblastoma cells. J. Cell. Physiol. 2015, 230, 1713–1728.
30. Wang, L.; Gai, P.; Xu, R.; Zheng, Y.; Lv, S.; Li, Y.; Liu, S. Shikonin protects chondrocytes from interleukin-1β-induced apoptosis by regulating PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol. 2015, 8, 298–308.
31. Wada, N.; Kawano, Y.; Fujiwara, S.; Kikukawa, Y.; Okuno, Y.; Tasaki, M.; Ueda, M.; Ando, Y.; Yoshinaga, K.; Ri, M. et al. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. Int. J. Oncol. 2015, 46, 963–972.
32. Hu, Y.; Cheng, P.; Ma, J.C.; Xue, Y.X.; Liu, Y.H. Platelet-derived growth factor BB mediates the glioma-induced migration of bone marrow-derived mesenchymal stem cells by promoting the expression of vascular cell adhesion molecule-1 through the PI3K, P38 MAPK and NF-κB pathways. Oncol. Rep. 2013, 30, 2755–2764.
33. Trog, D.; Yeghiazaryan, K.; Schild, H.H.; Golubnitschaja, O. Engineering of clinical glioma treatment: Prediction of pro-invasive molecular events in treated gliomas. Proc. Inst. Mech. Eng. H 2008, 222, 1149–1160.
34. Zhao, J.X.; Yang, L.P.; Wang, Y.F.; Qin, L.P.; Liu, D.Q.; Bai, C.X.; Nan, X.; Shi, S.S.; Pei, X.J. Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells. Eur. J. Neurol. 2007, 14, 510–516.
35. Wang, M.; Yoshida, D.; Liu, S.; Teramoto, A. Inhibition of cell invasion by indomethacin on glioma cell lines: In vitro study. J. Neurooncol. 2005, 72, 1–9.
36. Liu, X.; Wang, L.; Zhao, S.; Ji, X.; Luo, Y.; Ling, F. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med. Oncol. 2011, 28, 608–614.
37. Sareddy, G.R.; Panigrahi, M.; Challa, S.; Mahadevan, A.; Babu, P.P. Activation of Wnt/β-catenin/ Tcf signaling pathway in human astrocytomas. Neurochem. Int. 2009, 55, 307–317.
38. Rossi, M.; Magnoni, L.; Miracco, C.; Mori, E.; Tosi, P.; Pirtoli, L.; Tini, P.; Oliveri, G.; Cosci, E.; Bakker, A. β-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol. Ther. 2011, 11, 753–761.
39. Yan, Z.; Wang, J.; Wang, C.; Jiao, Y.; Qi, W.; Che, S. miR-96/HBP1/Wnt/β-catenin regulatory circuitry promotes glioma growth. FEBS Lett. 2014, 588, 3038–3046.
40. Chen, X.; Hu, W.; Xie, B.; Gao, H.; Xu, C.; Chen, J. Downregulation of SCAI enhances glioma cell invasion and stem cell like phenotype by activating Wnt/β-catenin signaling. Biochem. Biophys. Res. Commun. 2014, 448, 206–211.
41. Chen, L.; Zhang, J.; Han, L.; Zhang, A.; Zhang, C.; Zheng, Y.; Jiang, T.; Pu, P.; Jiang, C.; Kang, C. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol. Rep. 2012, 27, 854–860.
42. Kataoka, Y.; Murley, J.S.; Patel, R.; Grdina, D.J. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int. J. Radiat. Biol. 2000, 76, 633–639.
43. Sadot, E.; Geiger, B.; Oren, M.; Ben-Ze'ev, A. Down-regulation of β-catenin by activated p53. Mol. Cell. Biol. 2001, 21, 6768–6781.
44. Cagatay, T.; Ozturk, M. P53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene 2002, 21, 7971–7980.
45. Luo, Y.; Sun, Z.; Li, Y.; Liu, L.; Cai, X.; Li, Z. Caudatin inhibits human hepatoma cell growth and metastasis through modulation of the Wnt/β-catenin pathway. Oncol. Rep. 2013, 30, 2923–2928.
46. Pooja, T.; Karunagaran, D. Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620. Eur. J. Pharmacol. 2014, 742, 55–64.
47. Zhao, C.; Zhang, M.; Liu, W.; Wang, C.; Zhang, Q.; Li, W. β-catenin knockdown inhibits pituitary adenoma cell proliferation and invasion via interfering with AKT and gelatinases expression. Int. J. Oncol. 2015, 46, 1643–1650.
48. Zhang, X.L.; Chen, M.L.; Zhou, S.L. Fentanyl inhibits proliferation and invasion of colorectal cancer via β-catenin. Int. J. Clin. Exp. Pathol. 2015, 8, 227–235.
49. Iwai, A.; Hijikata, M.; Hishiki, T.; Isono, O.; Chiba, T.; Shimotohno, K. Coiled-coil domain containing 85B suppresses the β-catenin activity in a p53-dependent manner. Oncogene 2008, 27, 1520–1526.
50. Zhang, L.Y.; Ye, J.; Zhang, F.; Li, F.-F.; Li, H.; Gu, Y.; Liu, F.; Chen, G.-S.; Li, Q. Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway. Int. J. Oncol. 2009, 35, 25–32.
51. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3, 317–330.
52. Ku, M.J.; Kim, J.H.; Lee, J.; Cho, J.Y.; Chun, T.; Lee, S.Y. Maclurin suppresses migration and invasion of human non-small-cell lung cancer cells via anti-oxidative activity and inhibition of the Src/FAK-ERK-β-catenin pathway. Mol. Cell. Biochem. 2015, 402, 243–252.
53. Tseng, C.H.; Tzeng, C.C.; Chiu, C.C.; Hsu, C.Y.; Chou, C.K.; Chen, Y.L. Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents. Bioorg. Med. Chem. 2015, 23, 141–148.
54. Ding, D.; Wei, S.; Song, Y.; Li, L.; Du, G.; Zhan, H.; Cao, Y. Osthole exhibits anti-cancer property in rat glioma cells through inhibiting PI3K/Akt and MAPK signaling pathways. Cell. Physiol. Biochem. 2013, 32, 1751–1760.
55. Li, P.; Zhou, C.; Xu, L.; Xiao, H. Hypoxia enhances stemness of cancer stem cells in glioblastoma: An in vitro study. Int. J. Med. Sci. 2013, 10, 399–407.
56. Shiozaki, A.; Bai, X.H.; Shen-Tu, G.; Moodley, S.; Takeshita, H.; Fung, S.Y.; Wang, Y.; Keshavjee, S.; Liu, M. Claudin 1 mediates TNFα-induced gene expression and cell migration in human lung carcinoma cells. PLoS ONE 2012, 7, e38049.
57. Roos, N.; Poulalhon, N.; Farge, D.; Madelaine, I.; Mauviel, A.; Verrecchia, F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J. Pharmacol. Exp. Ther. 2007, 321, 583–589.
58. Qi, S.; Song, Y.; Peng, Y.; Wang, H.; Long, H.; Yu, X.; Li, Z.; Fang, L.; Wu, A.; Luo, W. et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE 2012, 7, e38842.
59. Bai, J.; Mei, P.J.; Liu, H.; Li, C.; Li, W.; Wu, Y.P.; Yu, Z.Q.; Zheng, J.N. BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. J. Cancer Res. Clin. Oncol. 2012, 138, 991–998.
60. Cai, H.; Xue, Y.; Liu, W.; Li, Z.; Hu, Y.; Li, Z.; Shang, X.; Liu, Y. Overexpression of Roundabout4 predicts poor prognosis of primary glioma patients via correlating with microvessel density. J. Neurooncol. 2015, 123, 161–169.